Australian owned Biotech and Drug development Company. Established in 2015 when spun out of the University of Melbourne. Esfam targets human and animal diseases in the areas of oncology and viral infections. We are developing a new therapy for prostate cancer which has stopped responding to traditional treatment. Esfam is developing anti-cancer treatments against other common poorly responsive cancers such as pancreatic, ovarian and kidney, lung, colorectal, melanoma and breast cancer. We have developed a new therapy for treating COVID-19, which will complement vaccination. Our COVID-19 therapy is also expected to act a a preventative treatment, in people exposed to COVID-19. We are developing a new treatment for Cytomegalovirus (CMV), which is responsible for serious infections in immunosuppressed patients. CMV is also the commonest cause of cerebral palsy. Esfam is developing a new treatment for a common global viral infection affecting pigs Porcine respiratory and reproductive syndrome (PRRS).